Serum microRNAs are emerging as a clinically useful tool for early and non-invasive detection of various cancer types including renal cell carcinoma (RCC). Based on our previous results, we performed the study to analyze circulating serum miR-378 and miR-210 in patients with various histological subtypes of RCC. RNA was purified from blood serum samples of 195 RCC patients and 100 healthy controls. The levels of miR-378 and miR-210 in serum were determined absolutely using quantitative real-time PCR. Pre- and postoperative levels of both microRNAs were compared in 20 RCC patients. Significantly increased serum levels of both miR-378 and miR-210 enabled to clearly distinguish RCC patients and healthy controls with 80% sensitivity and 78% specificity if analyzed in combination (p<0.0001), and their levels significantly decreased in the time period of three months after radical nephrectomy (p<0.0001). Increased level of miR-378 positively correlates with disease-free survival (p=0.036) and clinical stage (p=0.0476). The analysis of serum miR-378 and miR-210 proved their potential to serve as powerful non-invasive diagnostic and prognostic biomarkers in RCC.

Central European Institute of Technology Masaryk University Brno 62500 Czech Republic

Department of Comprehensive Cancer Care Masaryk Memorial Cancer Institute Brno 65653 Czech Republic

Department of Urologic Oncology Masaryk Memorial Cancer Institute Brno 65653 Czech Republic

Department of Urology University Hospital Brno and Masaryk University Brno Brno 62500 Czech Republic

See more in PubMed

Yi Z., Fu Y., Zhao S., Zhang X., Ma C. Differential expression of miRNA patterns in renal cell carcinoma and nontumorous tissues. J. Cancer Res. Clin. Oncol. 2010;136:855–862. PubMed PMC

Eble J.N., Sauter G., Epstein J.I., Sesterhenn I.A. World Health Organization Classification of Tumours. IARC Press; Lyon, France: 2004. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs; p. 7.

Pichler M., Hutterer G.C., Chromecki T.F., Jesche J., Kampel-Kettner K., Eberhard K., Hoefler G., Pummer K., Zigeuner R. Trends of stage, grade, histology and tumour necrosis in renal cell carcinoma in a European centre surgical series from 1984 to 2010. J. Clin. Pathol. 2012;65:721–724. doi: 10.1136/jclinpath-2012-200797. PubMed DOI

Pichler M., Hutterer G.C., Chromecki T.F., Jesche J., Kampel-Kettner K., Pummer K., Zigeuner R. Renal cell carcinoma stage migration in a single European centre over 25 years: Effects on 5- and 10-year metastasis-free survival. Int. Urol. Nephrol. 2012;44:997–1004. doi: 10.1007/s11255-012-0165-5. PubMed DOI

Esquela-Kerscher A., Slack F.J. Oncomirs—MicroRNAs with a role in cancer. Nat. Rev. Cancer. 2006;6:259–269. doi: 10.1038/nrc1840. PubMed DOI

Taylor D.D., Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol. Oncol. 2008;110:13–21. doi: 10.1016/j.ygyno.2008.04.033. PubMed DOI

Redova M., Poprach A., Nekvindova J., Iliev R., Radova L., Lakomy R., Svoboda M., Vyzula R., Slaby O. Circulating miR-378 and miR-451 in serum are potential biomarkers for renal cell carcinoma. J. Transl. Med. 2012;10:55. doi: 10.1186/1479-5876-10-55. PubMed DOI PMC

Redova M., Poprach A., Besse A., Iliev R., Nekvindova J., Lakomy R., Radova L., Svoboda M., Dolezel J., Vyzula R., et al. MiR-210 expression in tumor tissue and in vitro effects of its silencing in renal cell carcinoma. Tumour Biol. 2013;34:481–491. doi: 10.1007/s13277-012-0573-2. PubMed DOI

Iwamoto H., Kanda Y., Sejima T., Osaki M., Okada F., Takenaka A. Serum miR-210 as a potential biomarker of early clear cell renal cell carcinoma. Int. J. Oncol. 2014;44:53–58. PubMed

Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., Peterson A., Noteboom J., O’Briant K.C., Allen A., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc. Natl. Acad. Sci. USA. 2008;105:10513–10518. doi: 10.1073/pnas.0804549105. PubMed DOI PMC

Mahn R., Heukamp L.C., Rogenhofer S., von Ruecker A., Müller S.C., Ellinger J. Circulating microRNAs (miRNA) in serum of patients with prostate cancer. Urology. 2011;77:e9–e16. doi: 10.1016/j.urology.2011.01.020. PubMed DOI

Huang Z., Huang D., Ni S., Peng Z., Sheng W., Du X. Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int. J. Cancer. 2010;127:118–126. doi: 10.1002/ijc.25007. PubMed DOI

Heneghan H.M., Miller N., Lowery A.J., Sweeney K.J., Newell J., Kerin M.J. Circulating microRNAs as novel minimally invasive biomarkers for breast cancer. Ann. Surg. 2011;251:499–505. doi: 10.1097/SLA.0b013e3181cc939f. PubMed DOI

Hauser S., Wulfken L.M., Holdenrieder S., Moritz R., Ohlmann C.H., Jung V., Becker F., Herrmann E., Walgenbach-Brünagel G., von Ruecker A., et al. Analysis of serum microRNAs (miR-26a-2*, miR-191, miR-337-3p and miR-378) as potential biomarkers in renal cell carcinoma. Cancer Epidemiol. 2012;36:391–394. doi: 10.1016/j.canep.2012.04.001. PubMed DOI

Zhao A., Li G., Péoc’h M., Genin C., Gigante M. Serum miR-210 as a novel biomarker for molecular diagnosis of clear cell renal cell carcinoma. Exp. Mol. Pathol. 2013;294:115–120. doi: 10.1016/j.yexmp.2012.10.005. PubMed DOI

Zanutto S., Pizzamiglio S., Ghilotti M., Bertan C., Ravagnani F., Perrone F., Leo E., Pilotti S., Verderio P., Gariboldi M., et al. Circulating miR-378 in plasma: A reliable, haemolysis independent biomarker for colorectal cancer. Br. J. Cancer. 2014;110:1001–1007. doi: 10.1038/bjc.2013.819. PubMed DOI PMC

Wang K., Yuan Y., Cho J.H., McClarty S., Baxter D., Galas D.J. Comparing the microRNA spectrum between serum and plasma. PLoS ONE. 2012;7:e41561. doi: 10.1371/journal.pone.0041561. PubMed DOI PMC

Circulating Non-coding RNAs in Renal Cell Carcinoma-Pathogenesis and Potential Implications as Clinical Biomarkers